Hemostemix Provides Corporate Update: Expanding Markets and Strengthening Intellectual Property

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a clinical-stage biotechnology company specializing in autologous cell therapies, has provided a corporate update highlighting its recent progress and future plans. The company's focus on using a patient's own stem cells to create treatments for severe cardiovascular and ischemic diseases, including Critical Limb Threatening Ischemia (CLTI), heart disease, and other regenerative needs, positions it well in the competitive biotechnology landscape.



Hemostemix's core product, ACP (Angiogenic Cell Precursors), has demonstrated significant clinical success in Phase II trials for CLTI. The therapy has shown the ability to heal ulcers in 83% of patients, reduce amputation rates to 4.8% compared to 25% in the control group, and decrease mortality rates significantly. This success, coupled with the company's strong intellectual property portfolio of 91 patents protecting its technology and processes globally, gives Hemostemix a robust competitive edge.



The company's strategic expansion into the Dominican Republic, announced on February 3, 2025, is a significant step towards geographical diversification. This move allows Hemostemix to tap into a new market with a growing demand for regenerative medicine treatments, providing access to a larger patient pool and potential for higher profit margins. The company's scalable production technology, the Automated Cell Therapy System (ACTS), enables regional and global scalability, further enhancing Hemostemix's ability to meet increased demand.

Hemostemix's recent up-listing on the OTCQB and TradeGateExchange has increased accessibility to American and European investors, potentially driving liquidity and valuation. The company's collaboration with 200 stem cell clinics and pursuit of regional joint ventures for production and distribution further strengthen its market position and sales path.